



# Transitioning From Parenteral Treprostinil to LIQ861 in a Patient With PAH

Sergio Mellado Flores, MD<sup>1</sup>; Savan Patel<sup>2</sup>; Rodolfo A. Estrada, MD<sup>3,4</sup>

<sup>1</sup>University of Texas Health at San Antonio, Division of Internal Medicine, <sup>2</sup>Liquidia Technologies, Morrisville, NC, <sup>3</sup>University of Texas Health at San Antonio, Division of Pulmonary and Critical Care, <sup>4</sup>South Texas Veterans Health Care System




## Introduction

- The INSPIRE study (NCT03399604) evaluated the long-term safety and tolerability of LIQ861 (dry powder treprostinil) in pulmonary arterial hypertension (PAH)
- The mean C<sub>max</sub> values for the 60- and 90-µg doses of inhaled treprostinil (1.59 and 1.74 ng/mL, respectively) were consistent with those for i.v. treprostinil at doses of 15 ng/kg/min given for 150 min in healthy volunteers (1.47 and 1.57 ng/mL, respectively)
- This is the first case report describing transitioning a patient with PAH from LIQ861 → i.v. treprostinil → LIQ861

## Case presentation

- This is a 42-year-old female with idiopathic PAH, oxygen-dependent, NYHA FC II, who was enrolled in the INSPIRE study and transitioned from nebulized TYVASO<sup>®</sup> (12 breaths QID) to LIQ861 (79.5 µg QID), in combination with sildenafil and macitentan
- LIQ861 was up-titrated to 132.5 µg QID (≥15 breaths of TYVASO<sup>®</sup> QID). By Day 1684, the patient improved 6MWD by 41 m and was NYHA FC I
- The patient subsequently lost insurance coverage for macitentan and was hospitalized on Day 1852 for right heart failure. She was transitioned in-hospital from LIQ861 to i.v. treprostinil 10 ng/kg/min
- The patient was successfully transitioned back to 185.5 µg QID of LIQ861 (≥21 breaths of TYVASO<sup>®</sup> QID) over several days in the hospital, in combination with sildenafil; ambrisentan was added a few weeks later
- LIQ861 was subsequently titrated to 212 µg QID (≥24 breaths of TYVASO<sup>®</sup> QID) to match risk stratification goals

## Case timeline



Abbreviations: 6MWD, 6-minute walk distance; i.v., intravenous; NYHA FC, New York Heart Association Functional Class; QID, 4 times a day; RHF, right heart failure; TID, 3 times a day.

Day	NYHA FC	6MWD (meters)	LIQ861 (µg QID)	i.v. treprostinil (ng/kg/min)	Sildenafil (40 mg TID)	Macitentan (10 mg QD)	Ambrisentan (10 mg QD)
0	II	386	79.5		✓	✓	
1684	I	427	132.5		✓	✓	
1821			132.5		✓		
1852	IV			15	✓		
1864				10	✓		
1887	III	320		10	✓		
1898				10	✓		✓
1920				10	✓		✓
1979			132.5	10	✓		✓
1985			185.5		✓		✓
2070		380	212		✓		✓
2105		294	212		✓		✓
2174	II	320	212		✓		✓

Abbreviations: 6MWD, 6-minute walk distance; i.v., intravenous; NYHA FC, New York Heart Association Functional Class; QD, daily; QID, 4 times a day; TID, 3 times a day.

## Medication characteristics



### Conclusion

Patients with PAH can be safely transitioned from i.v. treprostinil to LIQ861, achieving adequate tolerance and optimal therapeutic response

## References

- De Jesus Perez VA, Naeem D, Oldham WM, et al. Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension. *Am J Cardiol.* 2012;110(10):1546–1550.
- Raina A, Coons JC, Kanwar M, Murali S, Sokos G, Benza RL. Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension. *Pulm Circ.* 2013;3(1):116–120.
- Preston IR, Feldman J, White J, et al. Safety and efficacy of transition from inhaled treprostinil to parenteral treprostinil in selected patients with pulmonary arterial hypertension. *Pulm Circ.* 2014;4(3):456–461.
- Smith ZR, Kelly B, Awdish RL, Hegab S. Transitioning parenteral or inhaled treprostinil to oral treprostinil diolamine: case series and review of the literature. *J Pharm Pract.* 2019;32(5):599–604.